1. A FIRST‐IN‐HUMAN STUDY OF A HALF‐LIFE EXTENDED CD19‐TARGETING BiTE IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA OR FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Popplewell, L.; Verhoef, G.; Kuruvilla, J.; Tuglus, C.; Kischel, R.; Stieglmaier, J.; Ghobadi, A. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 566 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Preclinical characterization of an EGFRvIII/CD3 specific BiTE® antibody construct for the treatment of glioblastoma multiforme. (December 2016) Authors: Kischel, R.; Sternjak, A.; Wahl, J.; Herrmann, I.; Thomas, O.; Balazs, M.; Voelkel, M.; Stienen, S.; Rattel, B.; Kufer, P.; Friedrich, M.; Muenz, M. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S96 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗